EXEL vs FBRX
Exelixis vs Forte Biosciences, Inc. — AI-powered side-by-side comparison
VS
FBRX
Forte Biosciences, Inc.
59
Watch
| Metric | EXEL | FBRX |
|---|
| AI Score |
67
|
59
|
| Price |
$51.30
|
$76.88
|
| P/E Ratio |
15.60×
|
-16.78×
|
| ROE |
36.2%
|
-113.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
0.0%
|
| Debt / Equity |
0.09×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
41.0
|
85.6
|
| Beta |
0.422
|
2.645
|
| Expected Upside |
+8.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for EXEL versus FBRX.
EXEL leads by 8 points.
EXEL scores 67/100 (Buy) versus FBRX at 59/100 (Watch).
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
FBRX Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 80.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 86 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 92 -- overbought on the larger timeframe too — Technical